What is pulmonary hypertension and why would a new GLP-1 help?
Get the Health newsletter
Daily health & science — research, biotech, public health, the studies worth knowing. Free.
- STAT reported that a 79-year-old with obesity, sleep apnea, and pulmonary hypertension received Eli Lilly's experimental drug retatrutide in April under a compassionate use program typically reserved for terminally ill patients.
- The White House initially declined to say whether the mystery patient was President Trump, then told STAT after publication that the drug was not for the president.
- Pulmonary hypertension is an umbrella term covering five distinct groups affecting ~1% of the global population (~82 million people), ranging from rare arterial forms to common cardiometabolic cases that account for ~60% of patients in Group 2.
- A Vanderbilt University preprint on medRxiv (September 2025) found an association between GLP-1 use and lower PH risk in a large retrospective study of U.S. veterans with type 2 diabetes, though it has not been peer-reviewed.
- NYU Langone's Roxana Sulica said she would rename pulmonary hypertension to distinguish Group 1 arterial patients from Group 2 cardiometabolic patients, calling them essentially different diseases.
- University of Michigan's Vallerie McLaughlin said GLP-1s may help PH patients with heart failure with preserved ejection fraction through anti-inflammatory effects and reduced cardiac strain, calling the scientific rationale promising but unproven.
Why it matters: If clinical trials confirm the early signals linking GLP-1s to reduced pulmonary hypertension risk, the ~60% of PH patients in Group 2 — driven by obesity, sleep apnea, and heart failure — could gain a treatment option addressing the root metabolic causes rather than just symptoms. The compassionate use case also highlights how such programs are being applied beyond terminally ill patients for drugs not yet FDA-approved.
